Monday, 16 July 2018 - 1:50
  • it
  • de
  • en
  • fr

COPD: Chronic Obstructive Pulmonary Disease

Novartis announces results of CRYSTAL trial in COPD

Novartis announced positive results from CRYSTAL, a prospective, open-label, multicenter, 12-week trial. Patients were recruited into four groups and randomized to a direct switch to Seebri Breezhaler (glycopyrronium) 50 mcg or Ultibro Breezhaler (indacaterol/glycopyrronium) 110/50 mcg once daily vs. continuation…

ERS, positive Phase III data for AstraZeneca’s benralizumab in asthma

The results from two Phase III trials, SIROCCO and CALIMA, designed to test benralizumab in patients with severe asthma, have been presented at the European Respiratory Society (ERS) Annual Congress. The results demonstrate that adding benralizumab to the standard-of-care therapy…

Chiesi fixed triple combination, positive results from two studies on COPD

The results from the TRILOGY study, designed to assess the extrafine fixed ICS/LABA/LAMA triple combination (beclomethasone/formoterol/glycopyrronium) developed by Chiesi, already published on the prestigious journal The Lancet, will be presented at the ERS (European Respiratory Society) Congress. The study demonstrates…

Ultibro Breezhaler vs Seretide for COPD: new findings

Published findings from new analyses within the FLAME study confirmed that Novartis’ Ultibro Breezhaler is more effective than Seretide for several subpopulations of patients with COPD. Once-daily Ultibro Breezhaler 110/50 mcg demonstrated consistent reductions in the rate of exacerbation, regardless…